US Stock MarketDetailed Quotes
SYRE Spyre Therapeutics
- 25.790
- +0.360+1.42%
Close Jun 18 16:00 ET
1.31BMarket Cap-567P/E (TTM)
26.300High24.470Low1.31MVolume25.250Open25.430Pre Close33.53MTurnover3.14%Turnover RatioLossP/E (Static)50.78MShares47.97052wk High-40.11P/B1.08BFloat Cap8.43052wk Low--Dividend TTM41.72MShs Float318.750Historical High--Div YieldTTM7.20%Amplitude2.650Historical Low25.618Avg Price1Lot Size
About Spyre Therapeutics Company
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Company Profile
SymbolSYRE
Company NameSpyre Therapeutics
Listing DateApr 7, 2016
Founded2013
CEODr. Cameron Turtle, D.Phil.
MarketNASDAQ
Employees30
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressBuilding 17,221 Crescent Street,Suite 102B
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-617-651-5940
Websitehttp://www.aeglea.com
Company Executives
- Name
- Position
- Salary
- Dr. Cameron Turtle, D.Phil.
- Director, President and Chief Executive Officer
- 15.92M
- Dr. Scott L. Burrows, M.D.
- Chief Financial Officer and Principal Accounting Officer
- 7.55M
- Heidy King-Jones
- Chief Legal Officer and Corporate Secretary
- 6.59M
- Jeffrey W. Albers, J.D.
- Chairman of the Board
- 433.57K
- Dr. Sandra Milligan, J.D.
- Director
- --
- Mark C. McKenna
- Independent Director
- --
- Dr. Michael Henderson, M.D.
- Independent Director
- --
- Laurie D. Stelzer, M.B.A.
- Independent Director
- 434.38K
- Tomas Kiselak
- Independent Director
- 658.43K
- Peter Harwin
- Independent Director
- 661.28K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg